{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-168351","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2026-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.925317+00:00","generated_at":"2026-05-15T04:54:55.470481+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Andrew King promoted to President, R&D at Jade Biosciences","bullets":["Andrew King previously CSO and Head of R&D appointed President Research & Development effective April 18 2026","No changes to Dr Kings compensation were made in connection with the appointment","King holds BVMS and Ph.D degrees and continues to lead R&D with expanded title"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-168351","json":"https://secwatch.observer/filing/0001193125-26-168351.json","markdown":"https://secwatch.observer/filing/0001193125-26-168351.md","text":"https://secwatch.observer/filing/0001193125-26-168351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526168351/0001193125-26-168351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526168351/d90643d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:54:55.470481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}